EUCTR2015-005046-55-SE进行中（未招募）1 期
Evaluation of [68Ga]PSMA PET/MRI in intermediate and high risk prostate cancer – a comparison with mpMRI, [11C]ACE PET/CT and histopathological validation
meå University Hospital0 个研究点开始时间: 2016年6月9日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •-Histologically confirmed intermediate/high risk prostate cancer
- •- =2 months since last biopsy of the prostate
- •- Gleason 3+4 or higher
- •-Written informed consent
- •-> 18 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •-Non MR-safe implants or other contraindication to MRI,PET or CT
- •-WHO PS>1
- •-TUR-P within 6 months
- •-Metastatic disease in skeleton, parenchymal organs or lymph nodes outside the pelvis
- •-Creatinine clearance < 30ml/min (acc. to http://www.fass.se/LIF/produktfakta-/kreatinin.jsp)
研究者
相似试验
进行中（未招募）
不适用
Prospective evaluation of 68-Ga-PSMA-PET and early PSA kinetics during salvage radiotherapy for personalizing the management of men with relapse of prostate cancer after radical prostatectomy.EUCTR2015-004425-13-SESkåne University Hospital, Department of Oncology100
进行中（未招募）
1 期
Evaluation of 68Ga-PSMA PET-CT in the initial extension assessment of advanced renal cell carcinomaa prospective, multicenter, open studyrenal cell cancer (RCC)EUCTR2019-003760-47-FRAssistance Publique Hôpitaux de Marseille44
招募中
不适用
68Gallium-Prostate Specific Membrane Antigen (68Ga-PSMA) Positron Emission Tomography (PET) as a potential Imaging biomarker post tyrosine kinase inhibition of metastatic clear cell Renal cell Carcinoma (PIRC) – a pilot studyclear cell renal cell carcinomaACTRN12621000651886Olivia Newton-John Cancer Research Institute20
已完成
不适用
A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive TumorsProstate-specific Membrane Antigen Positive TumorsBreast CancerProstate CancerLung CancerNCT02978586Case Comprehensive Cancer Center8
进行中（未招募）
1 期
Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management. The ProsPERo TrialMales 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on palliative systemic treatment and considered for further salvage therapyMedDRA version: 19.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10068979Term: Imaging procedureSystem Organ Class: 10022891 - InvestigationsEUCTR2016-000842-79-BEInstitut Jules Bordet75